Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.

PHARMA

Quarterly rpt on consolidated results for the financial period ended 31/12/2004

PHARMANIAGA BERHAD

Quarterly report for the financial period ended

31/12/2004
Quarter4
Financial Year End31/12/2004
The figureshave been audited

Attachments

pharma_klse_final.doc
441 KB

SUMMARY OF KEY FINANCIAL INFORMATION
31/12/2004


INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR CORRESPONDING QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR CORRESPONDING PERIOD
31/12/2004 
31/12/2003 
31/12/2004 
31/12/2003 
 
 
 
 
RM'000
RM'000
RM'000
RM'000
1Revenue
200,777
166,617
799,991
632,604
2Profit/(loss) before tax
22,264
18,664
81,778
66,841
3Profit/(loss)
after tax and minority
interest
13,368
9,495
50,835
40,756
4Net profit/(loss) for
the period
13,368
9,495
50,835
40,756
5Basic earnings/(loss) per share (sen)
13.12
9.47
50.18
40.70
6Dividend per share (sen)
10.50
8.50
15.00
12.00



AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net tangible assets per share (RM)

2.6000
2.2200

Note: For full text of the above announcement, please access KLSE Web site at www.klse.com.my


Remarks :
For the current financial year ended 31 December 2004, the Board of Directors recommends a final tax exempt dividend of 10.5 sen per share. The dates of entitlement and payment will be announced at a later date.


Announcement Info

Company NamePHARMANIAGA BERHAD  
Stock Name PHARMA    
Date Announced23 Feb 2005  
CategoryFinancial Results
Reference NoCC-050223-42602